These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37620196)

  • 1. Intravitreal fasudil monotherapy for treatment of refractory diabetic macular edema: A prospective interventional case series.
    Nourinia R; Nouri H; Abtahi SH; Nakao S; Eslamipour J; Gerami E; Ahmadieh H
    J Fr Ophtalmol; 2023 Nov; 46(9):1055-1060. PubMed ID: 37620196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
    Ahmadieh H; Nourinia R; Hafezi-Moghadam A; Sabbaghi H; Nakao S; Zandi S; Yaseri M; Tofighi Z; Akbarian S
    Br J Ophthalmol; 2019 Jul; 103(7):922-927. PubMed ID: 30150280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal fasudil combined with bevacizumab for treatment of refractory diabetic macular edema; a pilot study.
    Nourinia R; Ahmadieh H; Shahheidari MH; Zandi S; Nakao S; Hafezi-Moghadam A
    J Ophthalmic Vis Res; 2013 Oct; 8(4):337-40. PubMed ID: 24653821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The additive effect of intravitreal dexamethasone combined with bevacizumab in refractory diabetic macular edema.
    Karimi S; Karrabi N; Hassanpour K; Amirabadi A; Daneshvar K; Nouri H; Abtahi SH
    J Fr Ophtalmol; 2023 Nov; 46(9):1019-1029. PubMed ID: 37481454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal Fasudil for Treatment of Diabetic Macular Edema with an Unfavorable Response.
    Muto T; Machida S
    Semin Ophthalmol; 2022 Feb; 37(2):164-170. PubMed ID: 34384329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial.
    Ghanbari H; Kianersi F; Sonbolestan SA; Abtahi MA; Akbari M; Abtahi ZA; Abtahi SH
    Int Ophthalmol; 2017 Aug; 37(4):867-874. PubMed ID: 27624173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial.
    Ahmadieh H; Ramezani A; Shoeibi N; Bijanzadeh B; Tabatabaei A; Azarmina M; Soheilian M; Keshavarzi G; Mohebbi MR
    Graefes Arch Clin Exp Ophthalmol; 2008 Apr; 246(4):483-9. PubMed ID: 17917738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of combined treatment of bevacizumab and triamcinolone for diabetic macular edema refractory to previous intravitreal mono-injections.
    Yolcu Ü; Sobaci G
    Int Ophthalmol; 2015 Feb; 35(1):73-9. PubMed ID: 25425105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal injection of methotrexate in persistent diabetic macular edema: a 6-month follow-up study.
    Falavarjani KG; Golabi S; Modarres M
    Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2159-2164. PubMed ID: 27145784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema: a randomized double-blind clinical trial.
    Entezari M; Flavarjani ZK; Ramezani A; Nikkhah H; Karimi S; Moghadam HF; Daftarian N; Yaseri M
    Graefes Arch Clin Exp Ophthalmol; 2019 Nov; 257(11):2375-2380. PubMed ID: 31401683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.
    Rodrigues MW; Cardillo JA; Messias A; Siqueira RC; Scott IU; Jorge R
    Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):479-490. PubMed ID: 31873786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab.
    Ebrahimiadib N; Lashay A; Riazi-Esfahani H; Jamali S; Khodabandeh A; Zarei M; Roohipoor R; Khojasteh H; Bazvand F; Ojani M; Shahabinejad M; Yaseri M; Modjtahedi BS; Davoudi S; Riazi-Esfahani M
    Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):145-151. PubMed ID: 32211904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
    Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
    Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
    [No Abstract]   [Full Text] [Related]  

  • 14. CHANGES IN CENTRAL CHOROIDAL THICKNESS AFTER TREATMENT OF DIABETIC MACULAR EDEMA WITH INTRAVITREAL BEVACIZUMAB CORRELATION WITH CENTRAL MACULAR THICKNESS AND BEST-CORRECTED VISUAL ACUITY.
    Nourinia R; Ahmadieh H; Nekoei E; Malekifar P; Tofighi Z
    Retina; 2018 May; 38(5):970-975. PubMed ID: 28426622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pars plana vitrectomy versus three intravitreal injections of bevacizumab for nontractional diabetic macular edema. A prospective, randomized comparative study.
    Raizada S; Al Kandari J; Al Diab F; Al Sabah K; Kumar N; Mathew S
    Indian J Ophthalmol; 2015 Jun; 63(6):504-10. PubMed ID: 26265641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.
    Laiginhas R; Silva MI; Rosas V; Penas S; Fernandes VA; Rocha-Sousa A; Carneiro Â; Falcão-Reis F; Falcão MS
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):83-89. PubMed ID: 29082448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Abo-Elenin M
    Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal steroids for macular edema in diabetes.
    Rittiphairoj T; Mir TA; Li T; Virgili G
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005656. PubMed ID: 33206392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.